Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Going from immutable to mutable atherosclerotic plaques.

M J Davies1

  • 1British Heart Foundation, Cardiovascular Pathology Research Group, St. George's Hospital Medical School, University of London, London, United Kingdom. daviesmj@bhf.org.uk

The American Journal of Cardiology
|August 25, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.

Diabetes, obesity & metabolism·2008
Same author

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.

Diabetes, obesity & metabolism·2008
Same author

Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I.

Diabetologia·2008
Same author

Age influences the early events of skeletal muscle regeneration: studies of whole muscle grafts transplanted between young (8 weeks) and old (13-21 months) mice.

Experimental gerontology·2008
Same author

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.

British journal of cancer·2008
Same author

The DESMOND educational intervention.

Chronic illness·2008
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles

Statins effectively reduce the risk of acute coronary events by lowering lipids and influencing atherosclerotic plaque behavior. Early statin treatment is beneficial for high-risk patients with unstable coronary disease, reducing recurrent ischemic events.

Area of Science:

  • Cardiovascular Medicine
  • Inflammation Biology
  • Pharmacology

Background:

  • Atherosclerotic coronary disease is an inflammatory process following endothelial injury, leading to plaque disruption and acute coronary events.
  • Historically viewed as an irreversible aspect of aging, atherosclerotic plaque is now understood to be therapeutically modifiable.

Purpose of the Study:

  • To review the role of statins in managing atherosclerotic coronary disease.
  • To evaluate the impact of statins on lipid levels and plaque stability.
  • To assess the efficacy of early statin intervention in acute coronary syndromes.

Main Methods:

  • Review of clinical trial evidence on statin therapy in coronary disease.
  • Analysis of mechanisms underlying statin's cardioprotective effects beyond lipid lowering.

Related Experiment Videos

  • Evaluation of outcomes in patients with stable and unstable coronary disease treated with statins.

    • Main Results:

    • Statins significantly decrease the risk of acute ischemic events through lipid lowering and plaque modification.
    • Evidence supports statin use in stable coronary disease and early aggressive treatment in acute coronary syndromes.
    • Early statin therapy in acute coronary syndrome patients reduced recurrent ischemic events.

    Conclusions:

    • Statins are crucial for managing coronary disease, offering benefits beyond lipid reduction by stabilizing plaques.
    • Early and aggressive statin treatment is recommended for high-risk patients with acute coronary syndromes.
    • Further research is needed to understand event occurrence in treated patients and the role of non-lipid risk factors.